SLXN SLXN
Company Profile ↓Company Overview
SLXN (SLXN) is a publicly traded company listed on with a market capitalization of $562.80K. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -98.06% |
| 6 Months: | -89.83% |
| 3 Months: | -70.15% |
| 1 Month: | -34.31% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)33.83 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 98.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | 1.65M | 2.28M | 3.29M | 4.41M | 2.75M |
| Operating Income | -1.41M | -731.00K | -1.25M | -1.39M | -8.04M | - | -1.65M | -2.28M | -3.29M | -4.41M | -2.75M |
| EBITDA | - | - | - | - | - | - | -1.72M | -2.50M | -3.25M | -4.40M | -2.75M |
| Interest Expense | - | - | - | - | - | - | 9.00K | 0 | 4.00K | 6.00K | - |
| Pretax Income | - | - | - | - | - | - | -1.74M | -2.50M | -3.26M | -4.41M | -2.73M |
| Tax Provision | - | - | - | - | - | 1.00K | - | 3.00K | 0 | 0 | - |
| Net Income | -1.88M | -809.00K | -1.42M | -1.49M | -11.86M | - | -1.74M | -2.50M | -3.26M | -4.41M | -2.73M |
| Diluted EPS | 6.54 | 0.78 | 12.29 | 197.80 | 274.25 | - | -39.00 | 43.20 | -28.80 | - | -8.50 |
| R&D Expense | 1.24M | 535.00K | 961.00K | 766.00K | 3.22M | - | 590.00K | 1.02M | 2.16M | - | 1.37M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 3.86M | 4.68M | 12.57M | 11.63M |
| Operating Income | -3.86M | -4.68M | -12.57M | -11.63M |
| EBITDA | -3.80M | -5.03M | -16.48M | -11.88M |
| Interest Expense | - | 6.00K | 7.00K | 13.00K |
| Pretax Income | -3.46M | -5.08M | -16.51M | -11.91M |
| Tax Provision | 24.00K | 32.00K | 10.00K | 3.00K |
| Net Income | -3.21M | -4.94M | -16.44M | -11.91M |
| Diluted EPS | -532.46 | -818.48 | -3,949.40 | -89.60 |
| R&D Expense | - | 3.71M | 5.82M | 7.14M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 9.33M | 5.26M | 2.86M | 7.21M |
| Current Assets | 8.84M | 4.98M | 2.25M | 6.64M |
| Cash & Equivalents | 8.26M | 4.59M | 1.19M | 5.99M |
| Inventory | - | - | - | - |
| Receivables | - | - | - | - |
| Total Liabilities | 16.41M | 17.31M | 6.85M | 4.61M |
| Current Liabilities | 1.61M | 2.20M | 3.52M | 2.76M |
| Long Term Debt | - | - | 2.96M | 1.57M |
| Total Debt | 271.00K | 171.00K | 4.49M | 2.04M |
| Total Equity | -10.66M | -15.48M | -3.99M | 2.60M |
| Shares Outstanding | 6.04K | 6.04K | 12.33K | 312.67K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -3.33M | -4.53M | -8.40M | -10.82M |
| Investing Cash Flow | -524.00K | 573.00K | -22.00K | -14.00K |
| Financing Cash Flow | 2.75M | 522.00K | 5.10M | 15.64M |
| Capital Expenditure | -40.00K | -12.00K | -22.00K | -9.00K |
| Free Cash Flow | -3.38M | -4.54M | -8.42M | -10.83M |
| Net Change in Cash | -1.11M | -3.43M | -3.31M | 4.81M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 30.1% | 31.9% | 412.2% | -457.6% |
| ROCE % | -50.0% | -153.0% | 1,904.7% | -261.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SLXN
Silexion's SIL204 Alters Three Immune Pathways in Cancer Cells - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQWmtuQUYtRjhjWmpUaFI5NUNLemlZLXJYYU1uc3dISEszVU92SWRHczQyXy1wMUdJUi1TYXg1NXZvNklHQXB5YllFeXV5MGZ2WnpyNnRjWTRmUWdWZjRDY3FYVjZ0Uk1IbDhMUTUwSHRMOW8taFlTd1FwaS1TTEJhNFVlVThqSm1TaWFWb2…
Silexion Therapeutics (SLXN) spikes as investors react to mid-May clinical-trial milestones and fresh financing - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxPNHBjeHpYd2pETURtNVFLU1JMWksyLTVrbHhFczFiOVc4OTFVVWtYakZ3RXExUUlHeHRtck04aUF1bElxVVA2b2FCenMyUDJGZGFIYWxCYjNNbEhsTEhjc1RJLUFnME1qMlFpVDRCOERQYmJUVS0zcG4zNnROWE1NeG9rbmZBRFppeHd4U3…
SLXN Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1fQW9SMHNGeHgwc0hzOG0zRTZIVHc4Z2tCXzBYRU9rMkMwbFB6eVdXYjNmdzBETjlMV1FpTkgzb2VKTy1BUlVNYmUtRGVmMDVETWF6OER5b21NZ05KbTFrY0kyR3draVlyWkU4RmZuRWVKTnY1LVNfWjhn?oc=5" target="_blank">SLX…
Traders are paying attention to the gapping stocks in Wednesday's session. - ChartMill
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxQN1UxcFpteHBEeGRMbFdSSXlaLWFHZVQ5NGcyT18zY1VBeGRmZDBIUEJ4ODJwTmVpVFMzcVY5LVZNQ25sbC1XaWpCZHdMeWMzWms5eFJRYW9PTjU4a2lqQ3ZCRGI1WmpmOHpvMDVJUXhjZDVKTXJBSXFTaV83OUY1dTVMLXVUaS00VVlzcH…
Silexion Therapeutics Shareholders Approve Capital Structure Changes - theglobeandmail.com
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxNOUk0TVk3X3RDNU1OeWtYMExWUEFFMlA3dTRoVlBUdUtzbVV1UXV3NXpZaURDUEhvVXVkUGpVdk5qU2huaWs5TEUwb01pQ1dac2VYa0xENDFPR0s0MVBVMEVxelVTcGRJN0ZvLTc4RVUyUnM0N1FyZjE5Xy11ZE10UGxYMW45NDN4ZlJJek…
Silexion Therapeutics Announces 1-for-10 Reverse Share Split - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxOc0pWeTZRVTNnNXhUWnVqZUhGX2lVeGdIREg4LVJiSnQ5cGNkUUZERG9YZkZhNzZLb1pQMUdMS1FPNzFkUjZYQ2NpR3BhdEJXOWVoWlAxLVFIUVQtNkhoQjJoTkNHYU5QYWZsaEU0cmZON3ZXUFdaZTFfWTJDTGZ5RGRFNE1YU3BCekJaUm…
SLXN — Frequently Asked Questions
What is the current share price of SLXN?
As of 2026-08-05 17:25 PDT, SLXN trades at $1.80 on NASDAQ/NYSE. Its 52-week range is $1.60 to $92.80.
What is the market capitalisation of SLXN?
SLXN has a market capitalisation of $562.80K on NASDAQ/NYSE.
What is the P/E ratio of SLXN?
SLXN trades at a trailing price-to-earnings (P/E) ratio of -0.02. Its price-to-book (P/B) ratio is 0.22.
Is SLXN a good stock to buy?
This page provides a data-driven analysis of SLXN, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.